PMA device
Avalus Ultra Bioprosthesis
Medtronic, Inc. · Heart-Valve, Non-Allograft Tissue (LWR, Class III) · First FDA decision Jan 31, 2024, newest Jan 31, 2024Aortic stenosisMitral regurgitationTricuspid regurgitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
1
Naming "Avalus Ultra Bioprosthesis"
MAUDE reports
0
Brand "Avalus Ultra Bioprosthesis", since 2015
PubMed studies
0
Mentioning "Avalus Ultra Bioprosthesis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Avalus Ultra Bioprosthesis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Avalus Ultra Bioprosthesis", any status and sponsor, newest update first.
- Avalus Ultra Post-Approval Study (PAS)Active, not recruiting
Medtronic Cardiac SurgeryPublic (MDT)
NCT06506903 · 190 participants · Start Nov 20, 2024 · Primary completion Nov 2026
Device: Medtronic Avalus Ultra · For: Aortic Valve Disease
Sites: Hartford, Connecticut; Gainesville, Florida; Atlanta, Georgia · 15 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Avalus Ultra Bioprosthesis", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LWR
17,256 reports: 871 malfunction, 15,439 injury, 934 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Avalus Ultra Bioprosthesis"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code LWR.
- Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2022
- St. Jude Medical Biocor and Biocor Supra ValvesAbbott Medical · PMA 2012
- INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2026
- Mitroflow Aortic Pericardial Heart ValveCorcym Canada Corp · PMA 2019
- TRIFORMIS RESILIA Tricuspid ValveEdwards Lifesciences, LLC · PMA 2026
- Perceval Sutureless Heart Valve, Perceval Plus Sutureless Heart ValveCorcym S.r.l. · PMA 2025
- Sjm Biocor Valve / Sjm Biocor Supra ValveAbbott Medical · PMA 2016
- Ats 3F Aortic Bioprosthesis Model 1000Medtronic, Inc. · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.